Sign Up to like & get
recommendations!
0
Published in 2021 at "Current medical research and opinion"
DOI: 10.1080/03007995.2021.1971182
Abstract: OBJECTIVE In the absence of a head-to-head study, we assessed the comparative effectiveness of pegcetacoplan, a targeted C3 complement inhibitor, vs. ravulizumab, a C5 complement inhibitor, among patients with paroxysmal nocturnal hemoglobinuria (PNH) previously treated…
read more here.
Keywords:
treated eculizumab;
ravulizumab;
pegcetacoplan;
comparative effectiveness ... See more keywords